Stock 2696 SHANGHAI HENLIUS BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

MarketScreener Strategies Shanghai Henlius Biotech, Inc.

Equities

2696

CNE100003N76

Delayed Hong Kong S.E.
Other stock markets
 02:40:23 2024-05-14 EDT 		5-day change 1st Jan Change
17.36 HKD +0.81% Intraday chart for Shanghai Henlius Biotech, Inc. +1.05% +25.04%
05-06 Henlius Biotech Gets US FDA Clearance for Phase 3 Trial of Gastric Cancer Combination Therapy MT
05-06 Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration CI

MarketScreener Strategies

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2696 Stock
  4. News Shanghai Henlius Biotech, Inc.
  5. MarketScreener Strategies
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW